Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 7,148 shares, a decrease of 65.8% from the June 15th total of 20,871 shares. Based on an average trading volume of 29,227 shares, the short-interest ratio is presently 0.2 days. Approximately 0.2% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Kiora Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 26th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kiora Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Price Performance

Shares of NASDAQ KPRX opened at $2.51 on Monday. Kiora Pharmaceuticals has a 1-year low of $1.76 and a 1-year high of $3.29. The company has a market capitalization of $11.12 million, a price-to-earnings ratio of -0.93 and a beta of -0.40. The business has a 50-day moving average of $2.58 and a 200-day moving average of $2.31.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its earnings results on Friday, May 8th. The company reported ($0.58) EPS for the quarter, meeting the consensus estimate of ($0.58).

Institutional Trading of Kiora Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. purchased a new position in shares of Kiora Pharmaceuticals in the fourth quarter valued at $152,000. DRW Securities LLC grew its holdings in Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after purchasing an additional 73,417 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Kiora Pharmaceuticals during the 3rd quarter worth $125,000. Two Sigma Investments LP purchased a new stake in Kiora Pharmaceuticals during the 3rd quarter worth $33,000. Finally, Renaissance Technologies LLC lifted its holdings in Kiora Pharmaceuticals by 71.0% in the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after buying an additional 8,800 shares in the last quarter. Hedge funds and other institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.